# A Study to Evaluate the Safety and Efficacy of GR2002 Injection in Patients With Atopic Dermatitis.

> **NCT06175143** · PHASE1 · UNKNOWN · sponsor: **Genrix (Shanghai) Biopharmaceutical Co., Ltd.** · enrollment: 40 (estimated)

## Conditions studied

- Atopic Dermatitis

## Interventions

- **BIOLOGICAL:** GR2002 injection

## Key facts

- **NCT ID:** NCT06175143
- **Lead sponsor:** Genrix (Shanghai) Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-12
- **Primary completion:** 2024-10
- **Final completion:** 2024-10
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2023-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06175143

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06175143, "A Study to Evaluate the Safety and Efficacy of GR2002 Injection in Patients With Atopic Dermatitis.". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06175143. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*